Prophylactic antibiotics or G-CSF for the prevention of infections and improvement of survival in cancer patients undergoing chemotherapy

Cochrane Database of Systematic Reviews

Volumn , Issue 1, 2009, Pages

  Herbst, Christine ^a   Naumann, Frauke ^b   Kruse, Eva Brigitta ^c   Monsef, Ina ^a   Bohlius, Julia ^d   Schulz, Holger ^a   Engert, Andreas ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b Federal Institute for Drugs and Medical Devices (BfArM)   (Germany)

^c Deutsches Beratungszentrum für Hygiene   (Germany)

^d UNIVERSITY OF BERN   (Switzerland)

Author keywords

*Antibiotic prophylaxis; Antineoplastic combined chemotherapy protocols adverse effects ; Fever prevention control ; Granulocyte colony stimulating factor *therapeutic use ; Granulocyte macrophage colony stimulating factor *therapeutic use ; Humans; Infection control *methods ; Neoplasms *drug therapy; mortality ; Neutropenia prevention control ; Randomized controlled trials as topic

Indexed keywords

AMPHOTERICIN B; ANTIBIOTIC AGENT; CIPROFLOXACIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; IFOSFAMIDE; METHOTREXATE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; VINDESINE;

ANTIBIOTIC PROPHYLAXIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL TRIAL; DRUG EFFICACY; DRUG FATALITY; FEBRILE NEUTROPENIA; FEVER; HUMAN; INFECTION; INFECTION PREVENTION; LEUKOPENIA; LUNG SMALL CELL CANCER; META ANALYSIS; MORTALITY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; QUALITY OF LIFE; REVIEW; STEM CELL TRANSPLANTATION; SURVIVAL; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 70249128278     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007107.pub2     Document Type: Review

References (91)

1. Schroder CP, de Vries EG, Mulder NH, Willemse PH, Sleijfer DT, Hospers GA, et al.Prevention of febrile leucopenia after chemotherapy in high-risk breast cancer patients: no significant difference between granulocyte-colony stimulating growth factor or ciprofloxacin plus amphotericin B. Journal of Antimicrobial Chemotherapy 1999;43:741-743
2. Sculier JP, Paesmans M, Lecomte J, Van Cutsem O, Lafitte JJ, Berghmans T, et al.A three-arm phase III randomised trial assessing, in patients with extensive-disease small-cell lung cancer, accelerated chemotherapy with support of haematological growth factor or oral antibiotics. British Journal of Cancer 2001;85(10):1444-1451 (Pubitemid 34001571)
3. Ardizzoni A, Venturini M, Sertoli MR, Giannessi PG, Brema F, DanovaM, et al.Granulocyte-macrophage colony-stimulating factor (GM-CSF) allows acceleration and dose intensity increase of CEF chemotherapy: a randomised study in patients with advanced breast cancer. British Journal of Cancer 1994;69(2):385-391 (Pubitemid 24046569)
4. Bradstock K, Matthews J, Young G, Lowenthal R, Baxter H, Arthur C, et al.Effects of glycosylated recombinant human granulocyte colony-stimulating factor after high-dose cytarabine-based induction chemotherapy for adult acute myeloid leukaemia. Leukemia 2001;15(9):1331-1338 (Pubitemid 32785302)
5. Burton C, Linch D, Hoskin P, Milligan D, Dyer MJ, Hancock B, et al.A phase III trial comparing CHOP to PMitCEBO with or without G-CSF in patients aged 60 plus with aggressive non-Hodgkin's lymphoma. British Journal of Cancer 2006;94(6):806-813
6. Clarke V, Dunstan FD, Webb DK. Granulocyte colony-stimulating factor ameliorates toxicity of intensification chemotherapy for acute lymphoblastic leukemia. Medical & Pediatric Oncology 1999;32(5):331-335 (Pubitemid 29196280)
7. Dibenedetto SP, Ragusa R, Ippolito AM, Lo NL, Di Cataldo A, D'Amico S, et al.Assessment of the value of treatment with granulocyte colony-stimulating factor in children with acute lymphoblastic leukemia: a randomized clinical trial. European Journal of Haematology 1995;55(2):93-96
8. Faber E, Pytlik R, Slaby J, Zapletalova J, Kozak T, Raida L, et al.Individually determined dosing of filgrastim after autologous peripheral stem cell transplantation in patients with malignant lymphoma - results of a prospective multicentre controlled trial. European Journal of Haematology 2006;77(6):493-500. (Pubitemid 44690795)
9. Garcia G. Immediate vs. delayed imipenem treatment in cancer patients with profound neutropenia induced by high-dose chemotherapy: Results of a randomized study. Revista Espanola de Quimioterapia 2000; Vol.15:257-263
10. Garcia-Saenz JA, Martin M, Casado A, Perez-Segura P, Manrique I, Flores L, et al.Immediate vs. delayed imipenem treatment in cancer patients with profound neutropenia induced by high-dose chemotherapy: results of a randomized study. Revista Espanola de Quimioterapia 2002;15(3):257-263 (Pubitemid 35407923)
11. Geissler K, Koller E, Hubmann E, Niederwieser D, Hinterberger W, Geissler D, et al.Granulocyte colony-stimulating factor as an adjunct to induction chemotherapy for adult acute lymphoblastic leukemia - a randomized phase-III study. Blood 1997;90(2):590-596 (Pubitemid 27299098)
12. Gonzalez-Vicent M, Madero L, Sevilla J, Ramirez M, Diaz MA. A prospective randomized study of clinical and economic consequences of using G-CSF following autologous peripheral blood progenitor cell (PBPC) transplantation in children. Bone Marrow Transplantation 2004;34(12):1077-1081 (Pubitemid 40028841)
13. Greenberg P, Advani R, Keating A, Gulati SC, Nimer S, Champlin R, et al.GM-CSF accelerates neutrophil recovery after autologous hematopoietic stem cell transplantation. Bone Marrow Transplantation 1996;18(6):1057-1064 (Pubitemid 27026260)
14. Gulati SC, Bennett CL. Granulocyte-macrophage colony-stimulating factor (GM-CSF) as adjunct therapy in relapsed Hodgkin disease. Annals of Internal Medicine 1992;116(3):177-182
15. Heath JA, Steinherz PG, Altman A, Sather H, Jhanwar S, Halpern S, et al.Human granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia: a Children's Cancer Group Study. Journal of Clinical Oncology 2003;21(8):1612-1617 (Pubitemid 46594116)
16. Heil G, Hoelzer D, Sanz MA, Lechner K, Liu Yin JA, Papa G, et al.A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acutemyeloid leukemia. The International Acute Myeloid Leukemia Study Group. Blood 1997;90(12):4710-4718
17. Jones SE, Schottstaedt MW, Duncan LA, Kirby RL, Good RH, Mennel RG, et al.Randomized double-blind prospective trial to evaluate the effects of sargramostim versus placebo in a moderate-dose fluorouracil, doxorubicin, and cyclophosphamide adjuvant chemotherapy program for stage II and III breast cancer. Journal of Clinical Oncology 1996;14:2976-2983
18. Lalami Y, Paesmans M, Aoun M, Munoz-Bermeo R, Reuss K, Cherifi S, et al.A prospective randomised evaluation of G-CSF or G-CSF plus oral antibiotics in chemotherapy-treated patients at high risk of developing febrile neutropenia. Supportive Care in Cancer 2004;12(10):725-730 (Pubitemid 39362652)
19. Lee SM, Radford JA, Dobson L, Huq T, Ryder WD, Pettengell R, et al.Recombinant human granulocyte colony-stimulating factor (filgrastim) following high-dose chemotherapy and peripheral blood progenitor cell rescue in high-grade non-Hodgkin's lymphoma: clinical benefits at no extra cost. British Journal of Cancer 1998;77(8):1294-1299 (Pubitemid 28140619)
20. Little MA, Morland B, Chisholm J, Hole A, Shankar A, Devine T, et al.A randomised study of prophylactic G-CSF following MRC UKALL XI intensification regimen in childhood ALL and T-NHL. Medical & Pediatric Oncology 2002;38(2):98-103. (Pubitemid 34113438)
21. Maiche AG, Muhonen T.Granulocyte colony-stimulating factor (GCSF) with or without a quinolone in the prevention of infection in cancer patients. European Journal of Cancer 1993;29A(10):1403-1405
22. McQuaker IG, Hunter AE, Pacey S, Haynes AP, Iqbal A, Russell NH. Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economic benefit (Structured abstract). Journal of Clinical Oncology 1997;15(2):451-457 (Pubitemid 27074211)
23. Michel G, Landman-Parker J, Auclerc MF, Mathey C, Leblanc T, Legall E, et al.Use of recombinant human granulocyte colony-stimulating factor to increase chemotherapy dose-intensity: a randomized trial in very high-risk childhood acute lymphoblastic leukemia. Journal of Clinical Oncology 2000;18(7):1517-1524 (Pubitemid 30205398)
24. Miles DW, Fogarty O, Ash CM, Rudd RM, Trask CW, Spiro SG, et al.Received dose-intensity: a randomized trial of weekly chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer. Journal of Clinical Oncology 1994;12(1):77-82. (Pubitemid 2029088)
25. Nemunaitis J, Rosenfeld CS, Ash R, Freedman MH, Deeg HJ, Appelbaum F, et al.Phase III randomized, double-blind placebo-controlled trial of rhGM-CSF following allogeneic bone marrow transplantation. Bone Marrow Transplantation 1995;15(6):949-954.
26. Nolan L, Lorigan P, Chilton S, Newman J, Else R, Smith P, et al.Low-dose lenograstim is as effective as standard dose in shortening neutrophil engraftment time following myeloablative chemotherapy and peripheral blood progenitor cell rescue. British Journal of Haematology 2007;137(5):436-442 (Pubitemid 46698287)
27. Ojeda E, Garcia-Bustos J, Aguado M, Arrieta R, Quevedo E, Yuste VJ, et al.A prospective randomized trial of granulocyte colony-stimulating factor therapy after autologous blood stem cell transplantation in adults. Bone Marrow Transplantation 1999;24(6):601-607 (Pubitemid 29446133)
28. Ottmann OG, Hoelzer D, Gracien E, Ganser A, Kelly K, Reutzel R, et al.Concomitant granulocyte colony-stimulating factor and induction chemoradiotherapy in adult acute lymphoblastic leukemia: a randomized phase III trial. Blood 1995;86(2):444-450
29. Patte C, Laplanche A, Bertozzi AI, Baruchel A, Frappaz D, Schmitt C, et al.Granulocyte colony-stimulating factor in induction treatment of children with non-Hodgkin's lymphoma: a randomized study of the French Society of Pediatric Oncology. Journal of Clinical Oncology 2002;20(2):441-448 (Pubitemid 34072527)
30. Pettengell R, Gurney H, Radford JA, Deakin DP, James R, Wilkinson PM, et al.Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. Blood 1992;80(6):1430-1436
31. Piccirillo N, Sica S, Laurenti L, Chiusolo P, La Barbera EO, Sora F, et al.Optimal timing of G-CSF administration after CD34+ immunoselected peripheral blood progenitor cell transplantation. Bone Marrow Transplantation 1999;23(12):1245-1250 (Pubitemid 29312930)
32. Przepiorka D, Smith TL, Folloder J, Anderlini P, Chan KW, Korbling M, et al.Controlled trial of filgrastim for acceleration of neutrophil recovery after allogeneic blood stem cell transplantation from human leukocyte antigen-matched related donors. Blood 2001;97(11):3405-3410
33. Pui CH, Boyett JM, Hughes WT, Rivera GK, Hancock ML, Sandlund JT, et al.Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia. New England Journal of Medicine 1997;336(25):1781-1787 (Pubitemid 27262174)
34. Schmitz N, Ljungman P, Cordonnier C, Kempf C, Linkesch W, Alegre A, et al.Lenograstim after autologous peripheral blood progenitor cell transplantation: results of a double-blind, randomized trial. Bone Marrow Transplantation 2004;34(11):955-962 (Pubitemid 39600112)
35. Spitzer G, Adkins DR, Spencer V, Dunphy FR, Petruska PJ, Velasquez WS, et al.Randomized study of growth factors post-peripheral-blood stem-cell transplant: neutrophil recovery is improved with modest clinical benefit. Journal of Clinical Oncology 1994;12(4):661-670 (Pubitemid 24110902)
36. Stahel RA, Jost LM, Cerny T, Pichert G, Honegger H, Tobler A, et al.Randomized study of recombinant human granulocyte colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation for high-risk lymphoid malignancies. Journal of Clinical Oncology 1994;12(9):1931-1938 (Pubitemid 24349397)
37. Timmer-Bonte JN, de Boo TM, Smit HJ, Biesma B, Wilschut FA, Cheragwandi SA, et al.Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study. Journal of Clinical Oncology 2005;23(31):7974-7984 (Pubitemid 46657398)
38. Tjan-Heijnen VC, Caleo S, Postmus PE, Ardizzoni A, Burghouts JT, Buccholz E, et al.Economic evaluation of antibiotic prophylaxis in small-cell lung cancer patients receiving chemotherapy: an EORTC double-blind placebo-controlled phase III study (08923). Annals of Oncology 2003;14(2):248-257 (Pubitemid 36305437)
39. Trigg ME, Peters C, Zimmerman MB. Administration of recombinant human granulocyte-macrophage colony-stimulating factor to children undergoing allogeneic marrow transplantation: a prospective, randomized, double-masked, placebo-controlled trial. Pediatric Transplantation 2000;4(2):123-131 (Pubitemid 30316823)
40. Welte K, Reiter A, Mempel K, Pfetsch M, Schwab G, Schrappe M, et al.A randomized phase-III study of the efficacy of granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia. Berlin-Frankfurt-Munster Study Group. Blood 1996;87(8):3143-3150 (Pubitemid 26115342)
41. Witz F, Sadoun A, Perrin MC, Berthou C, Briere J, Cahn JY, et al.A placebo-controlled study of recombinant human granulocyte-macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients. Groupe Ouest Est Leucemies Aigues Myeloblastiques (GOELAM). Blood 1998;91(8):2722-2730 (Pubitemid 28227521)
42. Yau JC, Neidhart JA, Triozzi P, Verma S, Nemunaitis J, Quick DP, et al.Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating-factor support for dose-intensive cyclophosphamide, etoposide, and cisplatin. American Journal of Hematology 1996;51(4):289-295 (Pubitemid 26117543)
43. Zinzani PL, Pavone E, Storti S, Moretti L, Fattori PP, Guardigni L, et al.Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma. Blood 1997;89(11):3974-3979 (Pubitemid 27220941)
44. Aapro MS, Cameron DA, Pettengell R, Bohlius J, Crawford J, Ellis M, et al.EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. European Journal of Cancer 2006;42(15):2433-2453 (Pubitemid 44442936)
45. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Annals of Internal Medicine 1966;64:328-340
46. Bodey GP. Infection in cancer patients. A continuing association. American Journal of Medicine 1986;81:11-26.
47. Bohlius J, Herbst C, Reiser M, Schwarzer G, Engert A. Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma. Cochrane Database of Systematic Reviews 2008, Issue 4. [DOI: 10.1002/14651858]
48. Bronchud MH, Potter MR, Morgenstern G, Blasco MJ, Scarffe JH, Thatcher N, et al.In vitro and in vivo analysis of the effects of recombinant human granulocyte colony-stimulating factor in patients. British Journal of Cancer 1988;58:64-69 (Pubitemid 18191201)
49. Bucaneve G, Micozzi A, Menichetti F, Martino P, Dionisi MS, Martinelli G, et al.. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. New England Journal of Medicine 2005;353:977-987 (Pubitemid 41262332)
50. Carratala J, Fernandez-Sevilla A, Tubau F, Callis M, Gudiol F. Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin. Clinical Infectious Diseases 1995;20:557-560
51. Clark OA, Lyman GH, Castro AA, Clark LG, Djulbegovic B. Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. Journal of Clinical Oncology 2005;23:4198-4214 (Pubitemid 46211326)
52. Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I, et al.Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. New England Journal of Medicine 1991;325:164-170
53. Cruciani M, Malena M, Bosco O, Nardi S, Serpelloni G, Mengoli C. Reappraisal with meta-analysis of the addition of Gram-positive prophylaxis to fluoroquinolone in neutropenic patients. Journal of Clinical Oncology 2003;21:4127-4137 (Pubitemid 46606180)
54. Cullen M, Steven N, Billingham L, Gaunt C, Hastings M, Simmonds P, et al.Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. New England Journal of Medicine 2005;353:988-998 (Pubitemid 41262333)
55. Dickersin K, Scherer R, Lefebre C. Identifying relevant studies for systematic reviews. BMJ 1994;309:1286-1291 (Pubitemid 24340510)
56. Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315(7109):629-634 (Pubitemid 27387172)
57. Elting LS, Cantor SB. Outcomes and costs of febrile neutropenia: adventures in the science and art of treatment choices. Support Care Cancer 2002;10(3):189-196
58. Engels EA, Lau J, Barza M. Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. Journal of Clinical Oncology 1998;16:1179-1187 (Pubitemid 28108756)
59. Gafter-Gvili A, Fraser A, Paul M, Leibovici L. Meta-Analysis: Antibiotic Prophylaxis Reduces Mortality in Neutropenic Patients. Annals of Internal Medicine 2005;142:979-995 (Pubitemid 40840313)
60. Gafter-Gvili A, Paul M, Fraser A, Leibovici L. Effect of quinolone prophylaxis in afebrile neutropenic patients on microbial resistance: systematic review and meta-analysis. Journal of Antimicrobial Chemotherapy 2007;59(1):5-22. (Pubitemid 46017895)
61. Griffin JD, Cannistra SA, Sullivan R, Demetri GD, Ernst TJ, Kanakura Y. The biology of GM-CSF: regulation of production and interaction with its receptor. International Journal of Cell Cloning 1990;8 Suppl 1:35-44.
62. Hackshaw A, Sweetenham J, Knight A. Are prophylactic haematopoietic growth factors of value in the management of patients with aggressive non-Hodgkin's lymphoma?. British Journal of Cancer 2004;90:1302-1305 (Pubitemid 38586251)
63. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 5.0.0 [updated February 2008]. http://www.cochrane.org/ resources/handbook/ (accessed 19 June 2008).
64. Holmes FA, Jones SE, O'Shaughnessy J, Vukelja S, George T, Savin M, et al.Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastimin chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. Annals of Oncology 2002;13(6):903-909 (Pubitemid 34752686)
65. Johnston E, Crawford J, Blackwell S, Bjurstrom T, Lockbaum P, Roskos L, et al.Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. Journal of Clinical Oncology 2000;18:2522-2528 (Pubitemid 30432517)
66. Jones SE, Schottstaedt MW, Duncan LA, Kirby RL, Good RH, Mennel RG, et al.Randomized double-blind prospective trial to evaluate the effects of sargramostim versus placebo in a moderate-dose fluorouracil, doxorubicin, and cyclophosphamide adjuvant chemotherapy program for stage II and III breast cancer. Journal of Clinical Oncology 1996;14:2976-2983
67. Karp JE, Merz WG, Hendricksen C, Laughon B, Redden T, Bamberger BJ, Bartlett JG, et al.Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. A randomized, double-blind, placebo-controlled trial. Annals of Internal Medicine 1987;106:1-7. (Pubitemid 17228300)
68. Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH.Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006;106:2258-2266 (Pubitemid 43673249)
69. Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. Journal of Clinical Oncology 2007;25(21):3158-3167 (Pubitemid 47218066)
70. Lau J, Ioannidis JP, Terrin N, Schmid CH, Olkin I. The case of the misleading funnel plot. BMJ 2006;333(7568):597-600.
71. Leibovici L, Paul M, Cullen M, Bucaneve G, Gafter-Gvili A, Fraser A, et al.Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions. Cancer 2006;107(8):1743-1751 (Pubitemid 44582942)
72. Lew MA, Kehoe K, Ritz J, Antman KH, Nadler L, Kalish LA, et al.Ciprofloxacin versus trimethoprim/sulfamethoxazole for prophylaxis of bacterial infections in bone marrow transplant recipients: a randomized, controlled trial. Journal of Clinical Oncology 1995;13(1):239-250
73. Lyman GH, Kuderer NM, Djulbegovic B. Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: A meta-analysis. American Journal of Medicine 2002;112:406-411 (Pubitemid 34246271)
74. Lyman GH. Pegfilgrastim: a granulocyte colony-stimulating factor with sustained duration of action.. Expert Opinion on Biological Therapy 2005;5(12):1635-1646
75. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUORUM statement. Quality of reporting of meta-analyses. Lancet 1999;354:1896-1900
76. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Clinical Oral Investigation 2003;7:2-7.
77. Morstyn G, Campbell L, Souza LM, Alton NK, Keech J, Green M, et al.Effect of granulocyte colony stimulating factor on neutropenia induced by cytotoxic chemotherapy. Lancet 1988;1:667-672 (Pubitemid 18083268)
78. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815-2834 (Pubitemid 28562978)
79. Paul M, Leibovici L. Systematic reviews and meta-analysis of febrile neutropenia. Mayo Clinical Proceedings 2005;80(9):1122-1125 (Pubitemid 41233349)
80. Pinto L, Liu Z, Doan Q, Bernal M, Dubois R, Lyman G. Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials. Current Medical Research & Opinion 2007;23(9):2283-2295 (Pubitemid 350246613)
81. Pizzo PA. Fever in immunocompromised patients. New England Journal of Medicine 1999;341(12):893-900.
82. Raanani P, Gafter-Gvili A, Paul M, Ben-Bassat I, Leibovici L, Shpilberg O. Immunoglobulin prophylaxis in hematological malignancies and hematopoietic stem cell transplantation. Cochrane Database of Systematic Reviews 2008, Issue 4. [DOI: 10.1002/14651858.]
83. Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, et al.2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. Journal of Clinical Oncology 2006;24:3187-3205 (Pubitemid 46638957)
84. Somolinos N, Arranz R, Del Rey MC, Jimenez ML. Superinfections by Escherichia coli resistant to fluoroquinolones in immunocompromised patients. Journal of Antimicrobial Chemotherapy 1992;30:730-731 (Pubitemid 23009024)
85. Sung L, Nathan PC, Lange B, Beyene J, Buchanan JR. Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: A meta-analysis of randomized controlled trials. Journal of Clinical Oncology 2004;22:3350-3356 (Pubitemid 41103693)
86. Sung L, Nathan PC, Alibhai SM, Tomlinson GA, Beyene J. Meta-analysis: effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection. Annals of Internal Medicine 2007;147(6):400-411 (Pubitemid 351664541)
87. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16. (Pubitemid 47161711)
88. Timmer-Bonte JN, de Boo TM, Smit HJ, Biesma B, Wilschut FA, Cheragwandi SA, et al.Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study. Journal of Clinical Oncology 2005;23(31):7974-7984 (Pubitemid 46657398)
89. Trillet-Lenoir V, Green J, Manegold C, Von Pawel J, Gatzemeier U, Lebeau B, et al.Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. European Journal of Cancer 1993;29A:319-324 (Pubitemid 23025731)
90. von Minckwitz G, Kummel S, du BA, Eiermann W, Eidtmann H, Gerber B, et al.Pegfilgrastim +/- ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study. Annals of Oncology 2008;19(2):292-298 (Pubitemid 351201710)
91. Wittman B, Horan J, Lyman GH. Prophylactic colony-stimulating factors in children receivingmyelosuppressive chemotherapy: a meta-analysis of randomized controlled trials. Cancer Treatment Reviews 2006;32(4):289-303. (Pubitemid 44502006)